(Q35126976)

6 August 2017

1 reference

title

Redirecting T lymphocyte specificity using T cell receptor genes (English)

1 reference

6 August 2017

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

1

Barbara L. F. Kaplan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12745641

2 January 2024

author name string

David C. Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12745641

2 January 2024

Timothy M. Clay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12745641

2 January 2024

Michael I. Nishimura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12745641

2 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12745641

2 January 2024

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

http://www.tandfonline.com/doi/pdf/10.1080/08830180305227

1 reference

https://api.crossref.org/works/10.1080/08830180305227

International Reviews of Immunology

2 January 2024

published in

1 reference

6 August 2017

volume

22

1 reference

6 August 2017

issue

3-4

1 reference

6 August 2017

page(s)

229-253

1 reference

A new era for cancer immunotherapy based on the genes that encode cancer antigens

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Three-dimensional structure of an idiotope–anti-idiotope complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180305227

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

2 January 2024

2

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex

2 January 2024

3

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

2 January 2024

4

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

5

61

883

Reilly R.T.

2001

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Progress in human tumour immunology and immunotherapy

2 January 2024

6

1 reference

https://api.crossref.org/works/10.1080/08830180305227

The New England Journal of Medicine

2 January 2024

7

313

1492

Rosenberg S.A.

1985

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Clinical trials of antibody therapy

2 January 2024

11

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Role of HER2 gene overexpression in breast carcinoma

2 January 2024

12

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

2 January 2024

13

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

2 January 2024

14

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Herceptin (trastuzamab) in advanced breast cancer

2 January 2024

15

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Antibody-targeted immunotherapy for treatment of malignancy

2 January 2024

16

1 reference

https://api.crossref.org/works/10.1080/08830180305227

The biology of the 17-1A antigen (Ep-CAM)

2 January 2024

17

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

2 January 2024

18

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

2 January 2024

26

1 reference

https://api.crossref.org/works/10.1080/08830180305227

New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs.

2 January 2024

28

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

2 January 2024

30

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

2 January 2024

31

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response

2 January 2024

32

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

2 January 2024

33

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

2 January 2024

36

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene

2 January 2024

37

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

2 January 2024

39

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Immunochemical characterization of a human high molecular weight ? melanoma associated antigen identified with monoclonal antibodies

2 January 2024

40

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Clinical implications of the p53 tumor-suppressor gene

2 January 2024

41

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants

2 January 2024

42

1 reference

https://api.crossref.org/works/10.1080/08830180305227

p53 Mutations are present in colorectal cancer with cytoplasmic p53 accumulation

2 January 2024

43

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein

2 January 2024

44

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

46

54

1076

Disis M.L.

1994

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

2 January 2024

47

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene

2 January 2024

48

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

49

54

3390

Yoshino I.

1994

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

50

59

3142

Butterfield L.H.

1999

1 reference

https://api.crossref.org/works/10.1080/08830180305227

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein

2 January 2024

51

1 reference

https://api.crossref.org/works/10.1080/08830180305227

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

2 January 2024

54

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

2 January 2024

56

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

57

85

1206

Bocchia M.

2000

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

2 January 2024

59

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

2 January 2024

60

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

2 January 2024

62

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

2 January 2024

63

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

2 January 2024

64

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

2 January 2024

65

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

2 January 2024

67

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.

2 January 2024

69

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

2 January 2024

70

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

71

56

3787

Toes R.E.

1996

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Chimeric antigen receptors for the retargeting of cytotoxic effector cells

2 January 2024

73

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

2 January 2024

75

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Tumor-specific T-bodies: towards clinical application

2 January 2024

77

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

80

55

3373

Hwu P.

1995

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

2 January 2024

81

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

2 January 2024

83

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor

2 January 2024

86

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

90

55

752

Cole D.J.

1995

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Cancer Immunology, Immunotherapy

2 January 2024

91

36

8

Hom S.S.

1993

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes

2 January 2024

92

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Characterization of Lymphocytes Infiltrating Human Breast Cancer, Specific Immune Reactivity Detected by Measuring Cytokine Secretion

2 January 2024

93

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Human Cytotoxic Lymphocytes Reactive with Pancreatic Adenocarcinoma Cells

2 January 2024

95

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy

2 January 2024

96

1 reference

https://api.crossref.org/works/10.1080/08830180305227

A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma

2 January 2024

97

1 reference

https://api.crossref.org/works/10.1080/08830180305227

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

2 January 2024

98

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Human tumor antigens recognized by T cells

2 January 2024

100

1 reference

https://api.crossref.org/works/10.1080/08830180305227

T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines

2 January 2024

101

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

103

54

5268

Cole D.J.

1994

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Retroviral-mediated gene transfer in primary murine and human T-lymphocytes

2 January 2024

105

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production

2 January 2024

108

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus

2 January 2024

109

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection

2 January 2024

112

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide

2 January 2024

113

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes

2 January 2024

115

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

116

2

961

Kessels H.W.G.

2001

1 reference

https://api.crossref.org/works/10.1080/08830180305227

Regulation of p53 function

2 January 2024

117

1 reference

https://api.crossref.org/works/10.1080/08830180305227

2 January 2024

Identifiers

1 reference

6 August 2017

1 reference